摘要
原发中枢神经系统淋巴瘤（PCNSL）是原发于颅内的结外非霍奇金淋巴瘤，是一种罕见的高侵袭性淋巴瘤，预后较差。近年来，关于PCNSL的治疗方案尚无定论，以往的治疗包括手术、放疗、化疗等。目前大多认为综合治疗可以提高患者的生存率，而联合化疗药物的选择和预防性鞘内注射化疗药物在其治疗中占有重要地位。
Primary central nervous system lymphoma （PCNSL） is a kind of primary intracranial extranodal non-Hodgkin lymphoma, which is highly aggressive with rare incidence and poor prognosis. There is no consensus as to the standard regimen for treatment of PCNSL. The traditional regimen include surgery, radiotherapy and chemotherapy. However, the comprehensive treatment is regarded as the optimal therapy for the improvement of the survival rate, meanwhile, the combiantion of chemotherapy drugs and preventively intrathecal injection also play an important role in the therapy of PCNSL.
作者
高熠
张明智
吴晶晶
Gao Yi Zhang Mingzhi Wu Jingling(Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Chin)
出处
《白血病．淋巴瘤》
CAS
2017年第9期566-569,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金（81201793）
关键词
原发中枢神经系统淋巴瘤
药物疗法
联合
放疗
预后因素
Primary central nervous system lymphoma
Drug therapy, combination
Radiotherapy
Prognostic factors
